Vaikom Mahadevan, MD


Dr. Vaikom Mahadevan is a global leader in interventional cardiology for the treatment of adult congenital heart disease (ACHD) and structural heart disease. He has extensive experience performing adult congenital and transcatheter valvar interventions, including implantation of transcatheter valves in all four positions in the heart. He also has a strong interest in intracardiac echo imaging of the heart.

Before joining UCSF, Mahadevan served as a consultant cardiologist and interventionist at the Manchester Royal Infirmary, Central Manchester University Hospitals. In Manchester, he was director of the ACHD and transcatheter aortic valve replacement program, as well as director of the ACHD Interventional program for northwestern England. He also established and led the adult congenital pulmonary hypertension service for this region.

Mahadevan earned his medical degree from Stanley Medical College in Chennai, India, and received further training in internal medicine and cardiology in the U.K. He completed a fellowship in adult congenital heart disease and intervention at the Royal Brompton Hospital, London, followed by a fellowship in the same specialties at Toronto General Hospital in Ontario, Canada.

His clinical research interests include adult congenital and transcatheter valve implantation and pulmonary hypertension in ACHD. Mahadevan is a professor of medicine at UCSF.


Congenital Heart Disease Clinic
535 Mission Bay Blvd. South
San Francisco, CA 94158
Phone: (415) 353-2873
Fax: (415) 353-2528

Hours: Monday to Friday
8:00 a.m. – 4:30 p.m.

Academic Title


More about Vaikom Mahadevan


Stanley Medical College 1994


Doncaster 1997


Royal Brompton Hospital, Adult Congenital Heart Disease and Intervention 2004
Toronto General Hospital, Adult Congenital Heart Disease and Intervention 2005

Selected Research and Publications

  1. Marcus SG, Mahadevan VS, Deuse T. Hybrid Open Minimally-Invasive Transcatheter Mitral Valve Replacement. Ann Thorac Surg. 2018 Mar 29.
  2. Kheiwa A, Divanji P, Mahadevan VS. Transcatheter pulmonary valve implantation: will it replace surgical pulmonary valve replacement? Expert Rev Cardiovasc Ther. 2018 Mar; 16(3):197-207.
  3. Agarwal A, Cunnington C, Sabanayagam A, Zier L, McCulloch CE, Harris IS, Foster E, Atkinson D, Bryan A, Jenkins P, Dua J, Parker MJ, Karunaratne D, Moore JA, Meadows J, Clarke B, Hoschtitzky JA, Mahadevan VS. Cardiopulmonary exercise testing in the evaluation of liver disease in adults who have had the Fontan operation. Arch Cardiovasc Dis. 2017 Dec 01.
  4. Mukai K, Burris NS, Mahadevan VS, Foster ED, Ordovas KG, Hope MD. 4D flow image quality with blood pool contrast: a comparison of gadofosveset trisodium and ferumoxytol. Int J Cardiovasc Imaging. 2018 Feb; 34(2):273-279.
  5. Ganesan G, Paul GJ, Mahadevan VS. Transcatheter closure of left ventricle to right atrial communication using cera duct occluder. Indian Heart J. 2017 May - Jun; 69(3):341-344.
  6. Agarwal A, Harris IS, Mahadevan VS, Foster E. Coexistence of abnormal systolic motion of mitral valve in a consecutive group of 324 adult Tetralogy of Fallot patients assessed with echocardiography. Open Heart. 2016; 3(2):e000518.
  7. Kallianos K, Henry TS, Yeghiazarians Y, Zimmet J, Shunk KA, Tseng EE, Mahadevan V, Hope MD. Ferumoxytol MRA for transcatheter aortic valve replacement planning with renal insufficiency. Int J Cardiol. 2017 Mar 15; 231:255-257.
  8. Temple IP, Logantha SJ, Absi M, Zhang Y, Pervolaraki E, Yanni J, Atkinson A, Petkova M, Quigley GM, Castro S, Drinkhill M, Schneider H, Monfredi O, Cartwright E, Zi M, Yamanushi TT, Mahadevan VS, Gurney AM, White E, Zhang H, Hart G, Boyett MR, Dobrzynski H. Atrioventricular Node Dysfunction and Ion Channel Transcriptome in Pulmonary Hypertension. Circ Arrhythm Electrophysiol. 2016 Dec; 9(12).
  9. Zier LS, Sievert H, Mahadevan VS. To close or not to close: contemporary indications for patent foramen ovale closure. Expert Rev Cardiovasc Ther. 2016 Nov; 14(11):1235-1244.
  10. Calvert PA, Northridge DB, Malik IS, Shapiro L, Ludman P, Qureshi SA, Mullen M, Henderson R, Turner M, Been M, Walsh KP, Casserly I, Morrison L, Walker NL, Thomson J, Spence MS, Mahadevan VS, Hoye A, MacCarthy PA, Daniels MJ, Clift P, Davies WR, Adamson PD, Morgan G, Aggarwal SK, Ismail Y, Ormerod JO, Khan HR, Chandran SS, de Giovanni J, Rana BS, Ormerod O, Hildick-Smith D. Percutaneous Device Closure of Paravalvular Leak: Combined Experience From the United Kingdom and Ireland. Circulation. 2016 Sep 27; 134(13):934-44.
  11. Shah AH, Horlick EM, Eicken A, Asnes JD, Bocks ML, Boudjemline Y, Cabalka AK, Fagan TE, Schubert S, Mahadevan VS, Dvir D, Osten M, McElhinney DB. Transcatheter valve implantation for right atrium-to-right ventricle conduit obstruction or regurgitation after modified Bj÷rk-fontan procedure. Catheter Cardiovasc Interv. 2017 Feb 01; 89(2):298-305.
  12. Guerrero M, Dvir D, Himbert D, Urena M, Eleid M, Wang DD, Greenbaum A, Mahadevan VS, Holzhey D, O'Hair D, Dumonteil N, RodÚs-Cabau J, Piazza N, Palma JH, DeLago A, Ferrari E, Witkowski A, Wendler O, Kornowski R, Martinez-Clark P, Ciaburri D, Shemin R, Alnasser S, McAllister D, Bena M, Kerendi F, Pavlides G, Sobrinho JJ, Attizzani GF, George I, Nickenig G, Fassa AA, Cribier A, Bapat V, Feldman T, Rihal C, Vahanian A, Webb J, O'Neill W. Transcatheter Mitral Valve Replacement ináNativeáMitral Valve Disease With SevereáMitraláAnnular Calcification: Results From the First Multicenter Global Registry. JACC Cardiovasc Interv. 2016 07 11; 9(13):1361-71.
  13. Rendon A, Hamid T, Kanaganayagam G, Karunaratne D, Mahadevan VS. Annular sizing using real-time three-dimensional intracardiac echocardiography-guided trans-catheter aortic valve replacement. Open Heart. 2016; 3(1):e000316.
  14. Monfredi O, Heward E, Griffiths L, Condliffe R, Mahadevan VS. Effect of dual pulmonary vasodilator therapy in pulmonary arterial hypertension associated with congenital heart disease: a retrospective analysis. Open Heart. 2016; 3(1):e000399.
  15. Mahadevan VS, Manoly I, Hasan R. 2-Year Follow-Up of the First in Human Transapical Implantation of Transcatheter Inverted Aortic Valve to Treat Native Mitral Valve Stenosis. JACC Cardiovasc Interv. 2015 Dec 28; 8(15):e247-e249.
  16. Mahadevan VS, Dua J, Hoschtitzky A. Combined tricuspid and pulmonic valve percutaneous replacement in a patient with a Glenn shunt. Int J Cardiol. 2016 Feb 01; 204:128-30.
  17. Hamid T, Motwani M, Schneider H, Dua JS, Hoschtitzky A, Clarke B, Mahadevan VS. Benefit of endovascular stenting for aortic coarctation on systemic hypertension in adults. Arch Cardiovasc Dis. 2015 Dec; 108(12):626-33.
  18. Hamid T, Choudhury TR, Anderson SG, Hashmi I, Chowdhary S, Hesketh Roberts D, Fraser DG, Hasan R, Mahadevan VS, Levy R. Does the CHA2DS2-Vasc score predict procedural and short-term outcomes in patients undergoing transcatheter aortic valve implantation? Open Heart. 2015; 2(1):e000170.
  19. Hamid T, Jamallulail SI, Clarke B, Mahadevan VS. Dual Arterial Access for Stenting of Aortic Coarctation in Patients with Near-Total Descending Aortic Interruption. Cardiol Ther. 2015 Dec; 4(2):203-7.
  20. Kesarwani M, Ports TA, Rao RK, Mahadevan VS. First-in-Human Transcatheter Pulmonic Valve Implantation Through a Tricuspid Valve Bioprosthesis to Treat Native Pulmonary Valve Regurgitation Caused by Carcinoid Syndrome. JACC Cardiovasc Interv. 2015 Aug 24; 8(10):e161-3.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.